The company develops and markets health and wellness products, including air purification systems and digital health solutions through its KronosMD subsidiary. In 2023, the FDA granted 510(k) clearance to the company's manufacturer, classifying its Model 5 Air Purifier as a Class II Medical Device. Kronos can now deploy its medical-grade air purification and air disinfection technology in hospitals, home healthcare settings, schools, healthcare facilities, businesses, hotels, and government agencies.
Cyborg Score Rationale
The company faces significant financial challenges with fiscal 2024 revenues of only $21,103 and losses of $1.27 million. Despite FDA clearances and strategic initiatives (KronosMD subsidiary with dental imaging technology), the company operates as a microcap OTC stock with minimal revenue generation. Cash position and path to profitability remain unclear.
Top Insights
FDA 510(k) clearances for Models 5 and 8 provide regulatory pathway for hospital and healthcare facility deployment (2023)
KronosMD subsidiary pursuing S-WAVE™ dental imaging technology with AI integration as growth engine (January 2025)
Severe revenue decline: fiscal 2024 revenue collapsed 84% to just $21,103 from prior year's $135,931
Diversified technology portfolio spanning air purification, nuclear batteries, and dental health solutions creates uncertain strategic focus
Named Competitors
Air purifiers — Premium air purification and cooling devices
Home air quality systems — Building automation and air quality solutions
Medical-grade air purifiers — High-performance air filtration for healthcare
Recent Developments
(January 2025) Confirmed ownership structure for KronosMD subsidiary and announced seeking accredited investors to accelerate growth